PRW Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,595 shares of the company’s stock after buying an additional 210 shares during the period. PRW Wealth Management LLC’s holdings in Johnson & Johnson were worth $459,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of JNJ. Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter worth $26,000. Steward Financial Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at about $34,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at about $38,000. Advocacy Wealth Management Services LLC grew its holdings in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth about $49,000. 68.78% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of research analyst reports. Citigroup lowered their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating for the company. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.
Johnson & Johnson Price Performance
Johnson & Johnson stock opened at $171.31 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a fifty day simple moving average of $176.35 and a 200-day simple moving average of $174.34. The firm has a market capitalization of $450.79 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 3.42 and a beta of 0.63.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the company posted $2.48 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.01 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.
Insider Buying and Selling at Johnson & Johnson
In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.